...
首页> 外文期刊>International Journal of Molecular Sciences >Structure-Based Optimization of Inhibitors of the Aspartic Protease Endothiapepsin
【24h】

Structure-Based Optimization of Inhibitors of the Aspartic Protease Endothiapepsin

机译:天冬氨酸蛋白酶内皮抑素抑制剂的基于结构的优化

获取原文
           

摘要

Aspartic proteases are a class of enzymes that play a causative role in numerous diseases such as malaria (plasmepsins), Alzheimer’s disease (β-secretase), fungal infections (secreted aspartic proteases), and hypertension (renin). We have chosen endothiapepsin as a model enzyme of this class of enzymes, for the design, preparation and biochemical evaluation of a new series of inhibitors of endothiapepsin. Here, we have optimized a hit, identified by de novo structure-based drug design (SBDD) and DCC, by using structure-based design approaches focusing on the optimization of an amide–π interaction. Biochemical results are in agreement with SBDD. These results will provide useful insights for future structure-based optimization of inhibitors for the real drug targets as well as insights into molecular recognition.
机译:天冬氨酸蛋白酶是一类酶,在诸如疟疾(纤溶酶),阿尔茨海默氏病(β-分泌酶),真菌感染(分泌的天冬氨酸蛋白酶)和高血压(肾素)等多种疾病中起着致病作用。我们选择了内皮素胃蛋白酶作为此类酶的模型酶,用于一系列新的内皮素胃蛋白酶抑制剂的设计,制备和生化评估。在这里,我们通过使用基于结构的设计方法来优化酰胺-π相互作用,从而优化了由基于新结构的药物设计(SBDD)和DCC识别的命中。生化结果与SBDD一致。这些结果将为未来针对真实药物靶标的抑制剂的基于结构的优化提供有用的见识,并为分子识别提供见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号